Table 3.

Meta-analysis of the significant associations (P < 0.05) between risk variants for cancer and IMPC risk

WHI MEC
SNPFirst GWAS citationFirst GWAS siteRegionPositionMapped geneCaCoRisk allele/ref. alleleRAFMeta-ORa (95% CI)PDirectionbPhet for study
rs578776Saccone et al., 2009 (83)Nicotine dependence15q25.176,675,455CHRNA31,3779,559C/T0.491.15 (1.05–1.26)0.004++0.26
rs11249433Thomas et al., 2009 (68)Breast cancer1p11.2120,982,136EMBP11,3479,406C/T0.261.16 (1.04–1.28)0.005++0.59
rs3803662Thomas et al., 2009 (68)Breast cancer16q12.151,143,842TOX31,3779,577T/C0.401.13 (1.03–1.23)0.006++0.50
rs4975616Broderick et al., 2009 (15)Lung cancer5p15.331,368,660Intergenic1,3789,576A/G0.610.89 (0.82–0.98)0.0140.55
rs8042374Wang et al., 2008 (14)Lung cancer15q25.176,695,087CHRNA31,3689,550A/G0.571.12 (1.02–1.24)0.015++0.28
rs4857841Gudmundsson et al., 2009 (46)Prostate cancer3q21.3129,529,333EEFSEC1,3769,534A/G0.440.90 (0.82–0.98)0.0200.34
rs4785763Bishop et al., 2009 (31)Melanoma16q24.388,594,437AFG3L1P1,3709,551A/C0.281.11 (1.01–1.22)0.023++0.62
rs965513Gudmundsson et al., 2009 (46)Thyroid cancer9q22.3399,595,930Intergenic1,3779,562A/G0.240.89 (0.80–0.99)0.0260.42
rs5945619Eeles et al., 2008 (42)Prostate cancerXp11.2251,258,412Intergenic1,3789,566C/T0.271.09 (1.01–1.18)0.035++0.73
rs3790844Petersen et al., 2010 (19)Pancreatic cancer1q32.1198,274,055NR5A24202,657T/C0.771.23 (1.01–1.49)0.035+×1.00
rs10086908Al Olama et al., 2009 (29)Prostate cancer8q24.21128,081,119Intergenic9576,904T/C0.741.13 (1.01–1.27)0.040×+1.00
rs4939827Tenesa et al., 2008 (67)Colorectal cancer18q21.144,707,461SMAD71,3749,532T/C0.391.09 (1.00–1.19)0.047++0.18

Abbreviation: RAF, risk allele frequency.

  • aModels were adjusted for age at diagnosis for the index cancer (continuous), sex (MEC only), study design (WHI only: clinical trial vs. observational study), the most significant principal components.

  • b+, positive association; −, negative association; ×, not tested.